{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:06:14Z","timestamp":1790885174404,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jtct.2023.10.001","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T05:53:40Z","timestamp":1696485220000},"page":"118.e1-118.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1016","volume":"30","author":[{"given":"Chihiro","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7529-5585","authenticated-orcid":false,"given":"Daisuke","family":"Minakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daizo","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuka","family":"Furuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuto","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4397-0643","authenticated-orcid":false,"given":"Shunsuke","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8553-2975","authenticated-orcid":false,"given":"Takashi","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Murahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotomo","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nagayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Umino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2456-8189","authenticated-orcid":false,"given":"Kaoru","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ashizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masuzu","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9159-3398","authenticated-orcid":false,"given":"Kaoru","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2876-4224","authenticated-orcid":false,"given":"Kazuya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ohmine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4523-2994","authenticated-orcid":false,"given":"Shin-ichiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4866-9307","authenticated-orcid":false,"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.10.001_bib0001","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.10.001_bib0002","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.10.001_bib0003","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.10.001_bib0004","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2023.10.001_bib0005","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1002\/cncr.33809","article-title":"Longer-term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study","volume":"127","author":"Lonial","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2023.10.001_bib0006","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.10.001_bib0007","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.10.001_bib0008","series-title":"Poster presented at the 18th International Myeloma Workshop","article-title":"Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa","author":"Anderson","year":"2021"},{"key":"10.1016\/j.jtct.2023.10.001_bib0009","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2023.10.001_bib0010","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1: 2-year follow-up open-label study","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.001_bib0011","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1111\/bjh.17784","article-title":"Idecabtagene vicleucel: questions regarding the appropriate role and cost","volume":"196","author":"Powell","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2023.10.001_bib0012","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1200\/JCO.2018.79.0642","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia","volume":"36","author":"Lin","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.001_bib0013","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jnci\/djy193","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"111","author":"Sarkar","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jtct.2023.10.001_bib0014","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2019.5909","article-title":"Cost-effectiveness of tisagenlecleucel vs standard care in high-risk relapsed pediatric acute lymphoblastic leukemia in Canada","volume":"6","author":"Furzer","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2023.10.001_bib0015","article-title":"Cost-effectiveness analysis of tisagenlecleucel for the treatment of pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia in Japan","volume":"27","author":"Wakase","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.10.001_bib0016","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.001_bib0017","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood.2022016747","article-title":"Cost effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma","volume":"140","author":"Kambhampati","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.001_bib0018","doi-asserted-by":"crossref","first-page":"506.e1","DOI":"10.1016\/j.jtct.2021.03.005","article-title":"Cost effectiveness analysis of tisagenlecleucel for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma in Japan","volume":"27","author":"Wakase","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.10.001_bib0019","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jval.2021.07.008","article-title":"A systematic review of health technology assessments of chimeric antigen receptor T-cell therapies in young compared with older patients","volume":"25","author":"Gye","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.jtct.2023.10.001_bib0020","first-page":"1315","article-title":"Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma","volume":"27","author":"Beinfeld","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jtct.2023.10.001_bib0021","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40259-022-00557-3","article-title":"The economic burden of CAR T cell therapies ciltacabtagene autoleucel and idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma in the US","volume":"36","author":"Ghanem","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.jtct.2023.10.001_bib0022","unstructured":"Lee SJ, McQueen RB, Beinfeld M, et al. Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma; Final Evidence Report. Institute for Clinical and Economic Review, May 11, 2021. Available at: https:\/\/icer.org\/assessment\/multiple-myeloma-2021\/#timeline. Accessed April 19, 2023."},{"key":"10.1016\/j.jtct.2023.10.001_bib0023","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood.2021015220","article-title":"Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma","volume":"140","author":"Yamamoto","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.001_bib0024","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/bloodadvances.2021005913","article-title":"Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"6","author":"Delforge","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.10.001_bib0025","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1016\/S2352-3026(22)00284-8","article-title":"Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study","volume":"9","author":"Martin","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2023.10.001_bib0026","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.10.001_bib0027","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2023.10.001_bib0028","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1200\/JCO.20.01849","article-title":"Cost-effectiveness of first-line versus second-line use of daratumumab in older, transplant-ineligible patients with multiple myeloma","volume":"39","author":"Patel","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.001_bib0029","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jgo.2019.06.010","article-title":"Cost differential associated with hospice use among older patients with multiple myeloma","volume":"11","author":"Fiala","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jtct.2023.10.001_bib0030","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/hec.3871","article-title":"Frequentist and Bayesian meta-regression of health state utilities for multiple myeloma incorporating systematic review and analysis of individual patient data","volume":"28","author":"Hatswell","year":"2019","journal-title":"Health Econ"},{"key":"10.1016\/j.jtct.2023.10.001_bib0031","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-067975","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"376","author":"Husereau","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.jtct.2023.10.001_bib0032","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","article-title":"Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2023.10.001_bib0033","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41408-022-00662-0","article-title":"Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed\/refractory multiple myeloma: a single center analysis","volume":"12","author":"Parrondo","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2023.10.001_bib0034","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage treatment after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.10.001_bib0035","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1182\/blood-2021-147990","article-title":"Subsequent anti-myeloma therapy after idecabtagene vicleucel (ide-cel, bb2121) treatment in patients with relapsed\/refractory multiple myeloma from the KarMMa study","volume":"138","author":"Rodriguez-Otero","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.001_bib0036","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.001_bib0037","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2023.10.001_bib0038","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clml.2021.10.013","article-title":"Comparison of cilta-cel, an anti-BCMA CAR-T cell therapy, versus conventional treatment in patients with relapsed\/refractory multiple myeloma","volume":"22","author":"Costa","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2023.10.001_bib0039","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.10.001_bib0040","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723015816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723015816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:12:22Z","timestamp":1763003542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723015816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2666636723015816"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.10.001","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed\/Refractory Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}